Drug intelligence / Profile preview

copper-64

Development stage
Approved
Lead developer
Clarity Pharmaceuticals
Modality
Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Positron Emitters → Radiopharmaceuticals
Administration
Intravenous
01

Overview

Copper-64 is a versatile radioactive isotope used in nuclear medicine for both diagnostic imaging and targeted radionuclide therapy. With a half-life of approximately 12.7 hours, it primarily decays via positron emission (17.8%), making it highly suitable for high-resolution Positron Emission Tomography (PET) imaging. It also undergoes beta-minus decay (38.4%) and electron capture (43.8%), which allows for potential therapeutic applications through the emission of Auger electrons and beta particles. In clinical practice, copper-64 is typically chelated to targeting ligands such as peptides (e.g., DOTATATE), monoclonal antibodies, or small molecules to visualize specific biological markers like somatostatin receptors or PSMA. It is frequently utilized as the diagnostic component of a "theranostic" pair, often matched with the therapeutic isotope copper-67.

Brand names
Detectnet
Other names
Copper Cu 64Radioactive copper
02

Targets

SLC31A1 (Human copper transporter 1)PSMA (Prostate-specific membrane antigen)SSTR2 (Somatostatin receptor type 2)SSTR (Somatostatin receptors)

Beyond the preview

Go deeper on copper-64.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on copper-64.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call